Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6: 859-866.
Gurcan HM, Keskin DB, Stern JNH, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9: 10-25.
Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematol Am Soc Hematol Educ Program 2006; 432-7.
Collins PW. Therapeutic challenges in acquired factor VIII deficiency. Hematol Am Soc Hematol Educ Program 2012; 369-374
Baudo F, Collins P, Huth-Kuhne A, Levesque H, Marco P, Nemes L, Pellegrini F, Tengborn L, Knoebl P. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120: 39-46.
D’Arena G, Grandone E, Di Minno MND, Musto P, Di Minno G. Rituximab to treat adult acquired hemofilia A. Ann Hematol (submitted)
Franchini M, Mannucci PM. Inhibitor eradication with rituximab in haemophilia: where do we stand? Br J Haematol 2014; prepublishe online.